MedPath

US Post-Market Surveillance Study of the Surfacer System

Recruiting
Conditions
Venous Disease
Registration Number
NCT05050799
Lead Sponsor
Merit Medical Systems, Inc.
Brief Summary

Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.

Detailed Description

Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. A minimum of 30 patients will be enrolled in the study, all cases to be performed un-proctored at up to 12 sites in the United States, with no site enrolling more than 6 subjects. All patients enrolled will sign an informed consent form for use of their data. Investigators will invite patients who will be treated with the device in accordance with the approved labeling and who met enrollment criteria to join the study.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  1. Subjects have been referred for placement of central venous access, i.e., placement of catheter, nutritional line, etc.
  2. Subjects with upper body venous occlusions or other conditions that preclude central venous access by conventional methods
  3. Subjects are willing and able to give written informed consent
Exclusion Criteria
  1. Occlusion of the right femoral vein, right iliac vein or inferior vena cava
  2. Acute thrombus within any vessel to be crossed by Surfacer System (SVC, jugular, IVC, brachiocephalic and subclavian)
  3. Occlusion within the arterial system
  4. Occlusion within the coronary or cerebral vasculature

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of adverse events through 24 hours24 hours

no procedural adverse events or peri procedural adverse events

Central Venous Access operational24 hours

safe insertion of the device to facilitate central venous access

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

The University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

Pima Heart and Vascular

🇺🇸

Tucson, Arizona, United States

Sarasota Memorial Health Care System

🇺🇸

Sarasota, Florida, United States

Baylor Scott & White Heart and Vascular Hospital

🇺🇸

Dallas, Texas, United States

Flow Vascular Institute

🇺🇸

Pasadena, Texas, United States

St. Mark's Hospital

🇺🇸

Millcreek, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath